In this retrospective study, we analyzed the locoregional benefit of HER2+ breast cancer patients receiving RT with or without adjuvant trastuzumab, and assessed the impact of clinical and biological information, especially HR status, on the locoregional benefit of trastuzumab under this background. Here, ERBB2 is linked to breast carcinoma.